Area of research
Oncology · Genetics
Research interest
Research interests include Bone health and treatments, Estrogen and related hormone effects, Bone health and osteoporosis research, and Breast Cancer Treatment Studies.
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer
The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype
Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT
Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics – A retrospective analysis of a real world registry
Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status
Mutations in <i>BRCA1/2</i> and Other Panel Genes in Patients With Metastatic Breast Cancer —Association With Patient and Disease Characteristics and Effect on Prognosis
Bone health in cancer: ESMO Clinical Practice Guidelines
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany
Individualized Bone-Protective Management in Long-Term Cancer Survivors With Bone Metastases
Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine
Hormonersatztherapie und Prävention gemäß S3-Leitlinie
The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial.
Bone health during endocrine therapy for cancer
Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer
Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer
International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates
Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer
Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel
The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer
The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis